News

News

March 25, 2020

BioStock article: Follicum comments on patent notice for diabetes candidate

BioStock published an article on 25 March 2020 about Follicum, which can be read in full below. Follicum’s diabetes project took a big leap forward last Friday with a preliminary patent approval from the European Patent Office regarding the company’s diabetes peptides. BioStock contacted CEO Jan Alenfall to find out more about the project, the patent […]

March 9, 2020

BioStock article: Female alopecia – new solutions on the horizon

BioStock published an article on 9 March 2020 about female alopecia, which can be read in full below. Hair loss is common, and, while it does not necessarily come with any serious health complications, the stigma can be debilitating. This is especially true in women, who are often neglected in the discussions around alopecia. On […]

February 4, 2020

BioStock article: Follicum’s CEO comments on the study approval and Vinnova grant

BioStock published an article on 4 February 2020 about Follicum, which can be read in full below. FOL-005, Follicum’s hair growth candidate, has received approval from German authorities to initiate a phase IIa study. Patient recruitment will commence shortly, and initial results are expected before the end of the year. The company’s aim is to then […]

January 20, 2020

BioStock-article: The rise of therapeutic peptides: Follicum at the forefront

BioStock published an article on 20 January 2020 about Follicum, which can be read in full below. Pharmaceutical drugs are often subdivided into two fractions: small molecules and large molecules (or biologics). However, a third category called peptides falls right in-between, thus generating an overlap of benefits from the other classes of molecules. Follicum’s two projects, […]

December 18, 2019

BioStock article: 2019 in review: Follicum ready for phase II with hair loss candidate

BioStock published an article on 18 December 2019 about Follicum, which can be read in full below. Both of Follicum’s projects, FOL-005 and the diabetes peptides, have reached important milestones this year. A topical formulation of the company’s hair loss treatment has successfully completed toxicology and safety profile clinical studies, and Follicum is all set […]

December 17, 2019

BioStock-article: A double positive from Follicum

BioStock published an article on 17 December 2019 about Follicum, which can be read in full below. Yesterday, Follicum received a formal patent approval from the US Patent and Trademark Office protecting the hair project FOL-005 through 2032. In addition, the Lund-based company runs a diabetes project where previous preclinical studies have shown an ability […]

November 14, 2019

BioStock-article: Follicum approaches Phase II study with proDERM

BioStock published an article on 14 November 2019 about Follicum, which can be read in full below. Biotech company Follicum will conduct its upcoming Phase II study in hair loss together with the German CRO proDERM. The Charité Universitätsmedizin Berlin had previously been confirmed as a partner for the study, which is expected to start […]

October 22, 2019

BioStock-article: Follicum a step closer to phase II

BioStock published an article on 21 October 2019 about Follicum, which can be read in full below. Today, news broke that Follicum had completed the supplementary toxicology studies that will form the basis for the upcoming phase II trial with their topical formulation of FOL-005. The study results were positive, safeguarding the company’s expectation to initiate […]

September 30, 2019

BioStock-article: FOLLICUM IS CLOSING IN ON PROOF-OF-CONCEPT FOR HAIR LOSS PRODUCT

BioStock published an article on 30 September 2019 about Follicum, which can be read in full below. Follicum’s business strategy is to enter into a partnership, out license or sell their candidates following phase II trials at the latest. With proof-of-concept and top-line-data for FOL-005 firmly within reach during 2020, the company is getting closer […]